516 related articles for article (PubMed ID: 27979856)
1. 2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.
Tabas I
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):183-189. PubMed ID: 27979856
[TBL] [Abstract][Full Text] [Related]
2. Inflammation during the life cycle of the atherosclerotic plaque.
Libby P
Cardiovasc Res; 2021 Nov; 117(13):2525-2536. PubMed ID: 34550337
[TBL] [Abstract][Full Text] [Related]
3. The role of damage- and pathogen-associated molecular patterns in inflammation-mediated vulnerability of atherosclerotic plaques.
Rai V; Agrawal DK
Can J Physiol Pharmacol; 2017 Oct; 95(10):1245-1253. PubMed ID: 28746820
[TBL] [Abstract][Full Text] [Related]
4. The role of non-resolving inflammation in atherosclerosis.
Kasikara C; Doran AC; Cai B; Tabas I
J Clin Invest; 2018 Jul; 128(7):2713-2723. PubMed ID: 30108191
[TBL] [Abstract][Full Text] [Related]
5. Dead cell and debris clearance in the atherosclerotic plaque: Mechanisms and therapeutic opportunities to promote inflammation resolution.
Dhawan UK; Singhal A; Subramanian M
Pharmacol Res; 2021 Aug; 170():105699. PubMed ID: 34087352
[TBL] [Abstract][Full Text] [Related]
6. Macrophage Phenotype and Function in Different Stages of Atherosclerosis.
Tabas I; Bornfeldt KE
Circ Res; 2016 Feb; 118(4):653-67. PubMed ID: 26892964
[TBL] [Abstract][Full Text] [Related]
7. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.
McLaren JE; Michael DR; Ashlin TG; Ramji DP
Prog Lipid Res; 2011 Oct; 50(4):331-47. PubMed ID: 21601592
[TBL] [Abstract][Full Text] [Related]
8. Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect.
Fredman G; MacNamara KC
Cardiovasc Res; 2021 Nov; 117(13):2563-2574. PubMed ID: 34609505
[TBL] [Abstract][Full Text] [Related]
9. Inflammation and atherosclerosis: what is on the horizon?
Ruparelia N; Choudhury R
Heart; 2020 Jan; 106(1):80-85. PubMed ID: 31843811
[No Abstract] [Full Text] [Related]
10. The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis.
Ou H; Huang Z; Mo Z; Xiao J
Cardiovasc Toxicol; 2017 Jan; 17(1):1-12. PubMed ID: 27350146
[TBL] [Abstract][Full Text] [Related]
11. Adaptive Response of T and B Cells in Atherosclerosis.
Ketelhuth DF; Hansson GK
Circ Res; 2016 Feb; 118(4):668-78. PubMed ID: 26892965
[TBL] [Abstract][Full Text] [Related]
12. Atherosclerosis and immunity: A perspective.
Abdolmaleki F; Gheibi Hayat SM; Bianconi V; Johnston TP; Sahebkar A
Trends Cardiovasc Med; 2019 Aug; 29(6):363-371. PubMed ID: 30292470
[TBL] [Abstract][Full Text] [Related]
13. Functional diversity of macrophages in vascular biology and disease.
Park I; Kassiteridi C; Monaco C
Vascul Pharmacol; 2017 Dec; 99():13-22. PubMed ID: 29074468
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells in atherosclerosis: functions in immune regulation and beyond.
Manthey HD; Zernecke A
Thromb Haemost; 2011 Nov; 106(5):772-8. PubMed ID: 21901235
[TBL] [Abstract][Full Text] [Related]
15. Macrophages and dendritic cells: the usual suspects in atherogenesis.
Kassiteridi C; Monaco C
Curr Drug Targets; 2015; 16(4):373-82. PubMed ID: 25808566
[TBL] [Abstract][Full Text] [Related]
16. Inflammation in atherosclerosis.
Libby P
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2045-51. PubMed ID: 22895665
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.
Yurdagul A; Doran AC; Cai B; Fredman G; Tabas IA
Front Cardiovasc Med; 2017; 4():86. PubMed ID: 29379788
[TBL] [Abstract][Full Text] [Related]
18. Macrophage death and defective inflammation resolution in atherosclerosis.
Tabas I
Nat Rev Immunol; 2010 Jan; 10(1):36-46. PubMed ID: 19960040
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between efferocytic myeloid cells and T-cells and its relevance to atherosclerosis.
Ngai D; Sukka SR; Tabas I
Front Immunol; 2024; 15():1403150. PubMed ID: 38873597
[TBL] [Abstract][Full Text] [Related]
20. Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in Apob(tm2Sgy)Ldlr(tm1Her)/J mice.
Mundkur L; Mukhopadhyay R; Samson S; Varma M; Kale D; Chen D; Shivaprasad S; Sivanandan H; Soman V; Lu X; Kakkar VV
PLoS One; 2013; 8(3):e58364. PubMed ID: 23505495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
